PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
0.96%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.61%. Joel Greenblatt would investigate if growth quality matches quantity.
42.86%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.48%. Jim Chanos would check for structural cost disadvantages.
-116.90%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-116.74%
Margin decline while Drug Manufacturers - Specialty & Generic median is -0.80%. Seth Klarman would investigate competitive position.
-67.07%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-4.47%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
25.86%
Marketing expense change of 25.86% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
25.44%
Other expenses change of 25.44% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
9.97%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.09%. Jim Chanos would check for waste.
28.73%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.39%. Jim Chanos would check for waste.
646.45%
Interest expense change of 646.45% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-16.68%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.20%. Seth Klarman would investigate efficiency.
-242.73%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -0.18%. Seth Klarman would investigate causes.
492.57%
Margin change of 492.57% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
1962.12%
Income change of 1962.12% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
1942.56%
Margin change of 1942.56% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-89.29%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-1011.45%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is -11.33%. Seth Klarman would investigate causes.
-1002.80%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is -0.77%. Seth Klarman would investigate causes.
-107.81%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is -5.30%. Seth Klarman would investigate advantages.
-1159.97%
Net income decline while Drug Manufacturers - Specialty & Generic median is -12.03%. Seth Klarman would investigate causes.
-1149.92%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-1118.10%
EPS decline while Drug Manufacturers - Specialty & Generic median is -5.09%. Seth Klarman would investigate causes.
-1118.10%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -5.09%. Seth Klarman would investigate causes.
4.74%
Share count change of 4.74% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
4.12%
Diluted share change of 4.12% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.